CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (NASDAQ: CELZ) carries 10,633,425 warrants and options against a public float of roughly 6.55 million shares — meaning the company's derivative overhang, if fully exercised, would add 1.6 times the current tradeable supply.
That overhang did not appear overnight. It was built through four successive warrant-inducement rounds — a structure in which existing warrants are repriced lower, exercised for cash, and then replaced with double the number of new warrants at the reduced strike. Since October 2024, the strike progression has moved from $4.42 to $3.75 to $2.86 to $1.60, while the total warrant count has grown from roughly 2.3 million to over 10.6 million. Each cycle raised approximately $4 million in gross proceeds. Each cycle left a larger overhang behind.
The counterparties on every round are two institutional funds — Armistice Capital Master Fund and Hudson Bay Master Fund — intermediated by Roth Capital Partners as placement agent. Together, Armistice and Hudson Bay hold warrant positions totaling 7,307,391 shares, exceeding the company's entire 6,592,557 shares outstanding. Both funds use 4.99% beneficial ownership blockers — contractual caps that prevent their positions from triggering 13D/G disclosure requirements — so their selling, when it occurs, arrives with no public filing signal.
The August 28 vote changes everything
A special meeting scheduled for August 28, 2026 contains two proposals that function as structural gates. The first would grant Nasdaq Rule 5635(d) approval — a shareholder blessing required before a below-market private placement can close — unlocking 5,580,680 inducement warrants struck at $1.60. The second would raise authorized common shares from 25 million to 100 million, creating roughly 84.6 million unreserved shares. That headroom would equal roughly 13 times the current float.
The 25-million authorization ceiling is a real constraint today. Without the increase, the company cannot honor the full exercise of its existing warrants and simultaneously close a pending best-efforts offering — a deal structure in which the underwriter is not obligated to purchase unsold shares — registered on an S-1 filing. That S-1 could add up to 9.1 million additional shares: 3,045,685 common shares (or equivalent pre-funded warrants priced at $0.0001, which are economically identical to issued stock the moment they exist), plus 6,091,371 Public Warrants carrying a full-ratchet anti-dilution provision — meaning their exercise price automatically resets downward to match any future dilutive issuance at a lower price.
Float is already larger than screeners show
Shares outstanding reached 6,592,557 as of the July 24, 2026 S-3 filing — a resale registration statement that allows selling stockholders to offer shares into the open market. Most data services still reflect the June 30 proxy record-date count of approximately 4.74 million, understating the real tradeable supply by about 1.85 million shares, or 39%.
The share count trajectory tells its own story: 2,580,532 in November 2025; 3,696,668 by March 2026; 6,592,557 by late July. That is a 155% increase in nine months.
Insider alignment is minimal. All directors and officers combined hold approximately 35,000 issued shares — roughly 0.5% of outstanding. Two of five board members own zero shares. The securities purchase agreement governing the inducement warrants obligates management to keep calling stockholder meetings every 60 days until approval is obtained, embedding the dilution cycle into the company's contractual calendar.